Gastric Electrical Stimulators Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Gastric Electrical Stimulators Market Size
The global gastric electrical stimulators market is expected to experience noteworthy growth from 2025 to 2034, as a result of the rising prevalence of chronic gastrointestinal diseases and metabolic disorders like gastroparesis, obesity, and diabetes. Gastric electrical stimulators (GES), or gastric pacemakers, are implantable devices that help modulate gastric motility and enhance gastric emptying. Their increasing application in the treatment of advanced diabetic gastroparesis and postoperative gastroparesis, as well as their developing use in the management of functional dyspepsia, is driving their increasing adoption.
According to the World Obesity Federation, obesity has increased more than threefold in the world since 1975 and up to 2022. According to the 2024 report of the NCD Risk Factor Collaboration (NCD-RisC), more than one billion adults and children globally are now suffering from obesity, including almost 880 million adults and 159 million children and adolescents aged 5 to 19 years old. At the same time, The IDF Diabetes Atlas 2025 shows that 11.1% of adults aged between 20 and 79—or 1 in 9—now live with diabetes, of whom over 40% have not been informed about their disease. Forward to 2050, IDF estimates that 1 in 8 adults, or nearly 853 million, will have diabetes, a 46% increase. The direct causality of diabetes with gastroparesis, a condition that disables gastric motility and results in severe gastrointestinal symptoms, will be the key demand driver for gastric electrical stimulation therapy.
In addition, the increasing demand for alternative treatment methods because of the limited efficacy and side effects of prokinetic medications has directed medical attention toward implantable gastric stimulators. These systems provide minimally invasive, reversible, and adjustable treatment modalities—further driving market penetration.
Nonetheless, although they have advantages, gastric pacemakers are linked with complications like lead dislodgment, infection, bowel obstruction, and gastric perforation. These risks can retard adoption in certain areas with a lack of surgical expertise or inadequate patient compliance. Additionally, device-related expenses and reimbursement constraints in emerging economies can hinder market growth.
Nevertheless, rising clinical trials, FDA advances, and world regulatory endorsement will be anticipated to alleviate such hardships and establish gastric electrical stimulators as a worthwhile option for gastro-intestinal dysmotility care.
The gastric electrical stimulators industry is in the midst of a revolutionary technological shift. Contemporary devices are now being designed with AI-supported programming, real-time tracking, and wireless communication. AI-enabled GES can tailor stimulation patterns to patient feedback, maximizing therapy effectiveness and patient outcomes. In 2024, dominant players launched trials for adaptive gastric stimulators that adjust pulse delivery according to gastric sensor feedback, signaling a new era of precision medicine in motility disorders.
Integration of machine learning algorithms to forecast patient reactions and customize stimulation parameters is another interesting trend. In addition, Bluetooth-enabled gastric stimulators are facilitating remote monitoring, and clinicians can alter therapy settings without requiring multiple hospital visits—improving convenience and patient compliance.
The trend toward device miniaturization is gaining momentum, allowing for less invasive implantation procedures and greater patient comfort. New GES devices come with long-lasting batteries—some boasting up to 15 years of lifespan—thereby reducing the need for frequent surgical replacements. Additionally, biocompatible materials and flexible leads have minimized postoperative complications and device rejection rates.
Whereas GES systems were originally utilized in the treatment of refractory gastroparesis, their use is currently being expanded to treat a broader spectrum of GI motility disorders, such as functional dyspepsia, chronic nausea and vomiting, and even postoperative gastric dysrhythmias. This expanded clinical use has the potential to establish new revenue streams for device makers and expand the availability of GES for a greater patient population.
Regulatory agencies are providing expedited approvals for devices that fill unmet medical needs, particularly for complicated motility disorders. The U.S. FDA's breakthrough device designation for GES products for treating refractory gastroparesis, and comparable efforts by EMA and PMDA, are indicative of increased worldwide support. In the meantime, healthcare payers are gradually increasing coverage, particularly in North America and sections of Europe, where treatment-resistant gastrointestinal disorders are extremely common.
Of the various GES device types, the high-frequency stimulator segment is expected to lead the market between 2025 and 2034. These devices provide more uniform electrical pulses and are associated with quicker gastric emptying rates than their low-frequency counterparts. High-frequency systems also provide longer battery life, improved patient tolerance, and fewer side effects, leading both patients and physicians to prefer their use.
Another factor adding to segment growth is the rising trend towards minimally invasive interventions. High-frequency devices are usually compatible with laparoscopic implantation, cutting down on hospital stays and recovery times, hence enhancing procedural success and overall healthcare cost-effectiveness.
From the standpoint of application, the gastroparesis segment will remain the biggest contributor to the gastric electrical stimulators market. The condition, most often caused by long-duration diabetes, post-operative issues, or idiopathic causes, involves gastric motility and has a profound influence on the quality of life. Symptoms such as persistent nausea, bloating, and vomiting tend to be refractory to drug therapy, offering gastric stimulators as a realistic solution.
In addition, with diabetes a prime risk factor for gastroparesis, the increasing worldwide population of diabetics will drive GES adoption directly.
The obesity space is also picking up traction as bariatric surgeons consider utilizing GES as a tool to reduce appetite and aid in weight control. Although still in studies across much of the world, numerous clinical trials show positive findings, paving the way for approvals for future use of devices to treat obesity conditions.
The U.S. market for gastric electrical stimulators is anticipated to grow significantly up to 2034 with the support of well-developed healthcare infrastructure, availability of skilled gastroenterologists, and increasing patient awareness. With the high incidence of gastroparesis and a rising geriatric population, the requirement for efficient and less-invasive treatment procedures is increasing steadily.
The availability of prominent manufacturers and positive reimbursement coverage under Medicare for medically necessary GES devices further aid regional market growth. Robotic-assisted GES implantation is increasingly being adopted by hospitals and outpatient clinics throughout the U.S., demonstrating the region's focus on embracing advanced surgical technology.
Europe will see healthy market growth, dominated by Germany, France, and the U.K., where increased investment in digestive health and government expenditure on innovation is driving market trends. In Asia Pacific, China, Japan, and India are the markets promising great potential with advancing healthcare access and rising surgical proficiency. Furthermore, the incidence of diabetes and obesity is growing at unprecedented levels in these countries, driving demand for long-term treatment options such as GES.
Major players in the gastric electrical stimulators industry are:
These players are investing significantly in R&D, clinical trials, and strategic alliances to launch next-generation devices. Medtronic, for example, is upgrading its Enterra™ II system with digital interface enhancements and AI-based data analytics compatibility for treatment personalization.
Enterra Medical is also working on remote-capable GES devices that can obtain patient information and send it to clinicians in real time. These product developments will support the market leadership of existing players and contribute to their spread across new geographical markets.
In April 2024, the U.S. Food and Drug Administration (FDA) approved Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS), a healthcare technology leader Medtronic plc's new device for treating chronic pain. It is the first of Medtronic's SCS devices to incorporate closed-loop technology, which senses biological signals along the spinal cord and adjusts stimulation in real time automatically to keep pace with the body's natural motion during daily activities.
In February 2025, Medtronic obtained FDA clearance for its adaptive closed-loop neurostimulation system designed to control motor symptoms of Parkinson's disease. The company reports that this represents the largest US commercial launch of a brain-computer interface technology, using its BrainSense platform, which constantly tracks a patient's neural activity and adjusts therapy in real-time automatically to fine-tune treatment.